Drug Profile
Research programme: cardiovascular disease therapies - InNexus Biotechnology/ImmPheron
Alternative Names: S(T15) SuperAntibody; T-15Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Immpheron; InNexus Biotechnology
- Developer InNexus Biotechnology
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cardiovascular disorders
Most Recent Events
- 20 Jul 2005 This programme is still in active development - (BIO-2005)
- 27 Sep 2004 Preclinical trials in Cardiovascular disorders in Canada (unspecified route)
- 27 Sep 2004 Preclinical trials in Cardiovascular disorders in USA (unspecified route)